News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …
ARS Pharmaceuticals (NASDAQ:SPRY) announced its quarterly earnings, reporting a Q2 EPS loss of $0.63, missing analyst estimates by $0.15, although revenue of $33.66 million surpassed expectations. Despite improved Neffy sales and a strategic shift towards targeted provider outreach, the company faces key risks including …
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS stock fell significantly after the company announced …
ARS Pharmaceuticals reported Q2 2026 revenue of $33.7 million, exceeding analyst forecasts, but its shares fell significantly after hours due to concerns over high operating expenses and a delayed pipeline milestone. The company's intranasal epinephrine product, neffy, saw increased market share, and ARS Pharmaceuticals …
ARS Pharmaceuticals reported Q2 2026 financial results, including $26.2 million in U.S. neffy net product revenue. The company is shifting its commercial strategy to targeted provider engagement to reduce operating expenses and aims for cash flow breakeven by the end of 2027. ARS Pharma …
ARS Pharmaceuticals, Inc. (SPRY) reported a Q2 loss of $0.63 per share, missing the Zacks Consensus Estimate of a $0.55 loss. However, the company surpassed revenue estimates, posting $33.66 million against an expectation of 5.54% less. Despite underperforming the market year-to-date, the stock holds …
The Rosen Law Firm announces a class action lawsuit on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026. Investors who bought shares during this period are encouraged to secure counsel before the October 5, …
This article first appeared on GuruFocus. Total Revenue: $33.7 million in Q2 2026, reflecting a combination of net product, collaboration, and supply revenue. US Net Product Revenue: $26.2 million for the second quarter. Total Operating Expenses: $95.1 million in Q2 2026, including $12.8 million …
Robbins LLP is urging investors who suffered losses in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) between March 9, 2026, and June 24, 2026, to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline …
Hennion & Walsh Asset Management Inc. has acquired 175,614 shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) valued at approximately $1.4 million, representing a 0.18% stake in the company. Institutional investors now collectively own 68.16% of ARS Pharmaceuticals. The company faces mixed analyst ratings, a consensus …
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against ARS Pharmaceuticals, Inc. (SPRY), Alarum Technologies Ltd. (ALAR), and Blaize Holdings, Inc. (BZAI). The lawsuits allege false and misleading statements by the companies, with deadlines for lead plaintiff appointment set …
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $28.20. Despite this, the company faces a securities class-action lawsuit for investor purchases between March and June 2026, with a lead-plaintiff deadline of October …
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit stems from a 23.9% drop in ARS stock price after …
The Rosen Law Firm announces a class action lawsuit against ARS Pharmaceuticals, Inc. on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage timeline for …
ARS Pharmaceuticals (NASDAQ: SPRY) is facing a securities class action lawsuit, with investors having until October 5, 2026, to seek lead plaintiff status. The lawsuit alleges the company misled investors about the expected timeline for expanded insurance coverage for its allergy treatment, neffy, specifically …
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. and its officers on behalf of investors who purchased ARS securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company made misleading statements and …
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP reminds purchasers of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities of a pending securities class action brought on behalf of investors who acquired shares between March 9, 2026 and June 24, 2026. Find …
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) after the Company disclosed that its flagship product, Neffy®, received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle, contrary …
Robbins LLP has filed a securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals failed to disclose that expanded insurance coverage for …
The Rosen Law Firm has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the …
The Rosen Law Firm has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the timeline for expanded …
SueWallSt is alerting investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a securities class action lawsuit, with a lead plaintiff deadline of October 5, 2026. The lawsuit stems from a 23.9% stock decline after ARS Pharmaceuticals announced that CVS Caremark had postponed its formulary …
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by Holzer & Holzer, LLC, alleging the company made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. Investors who …
Faruqi & Faruqi, LLP reminds investors in ARS Pharmaceuticals (NASDAQ: SPRY) of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expected timeline …
ARS Pharmaceuticals, Inc. announced it will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During this event, President and CEO Donn Casale will detail the company's updated strategic priorities and disclose its second-quarter …
ARS Pharmaceuticals will host a conference call and webcast on August 13, 2026, to discuss its second quarter 2026 financial results and updated strategic priorities. CEO Donn Casale will present the information, focusing on the company's product neffy®, an epinephrine nasal spray for severe …
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. President and CEO Donn Casale will outline the company's updated strategic priorities and report second-quarter 2026 financial results. Investors can register …
ARS Pharmaceuticals Inc (SPRY) has a risk assessment score of 4.29, ranking 85 out of 385 in the Biotechnology & Medical Research industry, with a beta of 0.94 indicating it tends to underperform in bull markets and decline less in bear markets. The company's …
ARS Pharmaceuticals Inc (SPRY) currently has a financial score of 6.94, ranking 177 out of 384 in its industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue significantly increased by 184.47% year-over-year, reaching $22.68M, and its net profit …
Search by ticker symbol or company name and select a result to open its chart.